Medical Economics Podcasts: Staying current

Staying current with today's most pressing medical and practice management issues is just a click away. Choose a podcast to get started.

Listen Now

To listen now, please click one of the podcasts from the playlist below:


Download

To download a single podcast, right-click, or option-click, one of the links below and select "Save Target As...".

 

Does your practice need a nurse practitioner or physician assistant?
Telephone Triage
Health Plan Mergers
Locum Tenens
Primary Care Specialty
Physician Communication with Specialist
The Benefits of Cross-Training your Staff
Smarter Scheduling
Using PDAs in Your Practice
Tracking Tips
Improving Patient Education
Integrating Leadership into your practice
Employed Doctors
Increasing efficiency/effectiveness of your office space
Teamwork
Hospitalists
Patient Communication
Patient Education Strategies
Branding Your Practice
Tips to improve patient relations


Subscribe

To subscribe to these podcasts, copy the URL from below and paste it into your podcatching software.

Subscribe

Add to iTunes


Note: If you use a pop-up blocker, we recommend that you turn it off while downloading the above podcasts.

 

CONCERTA® is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

IMPORTANT SAFETY INFORMATION

CONCERTA® should not be taken by patients with: allergies to methylphenidate or other ingredients in CONCERTA®; significant anxiety, tension, or agitation; glaucoma; Tourette's syndrome, tics, or family history of Tourette's syndrome; current or recent use of monoamine oxidase inhibitors (MAOIs). Children under 6 years of age should not take CONCERTA.®

Abuse of methylphenidate may lead to dependence. CONCERTA® should not be used in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, other serious cardiac problems, or patients with pre-existing severe gastrointestinal narrowing. Use with caution in patients with hypertension and other cardiovascular conditions, psychosis, bipolar disorder, and history of seizures/EEG abnormalities. Stimulants may cause new psychotic or manic symptoms; discontinuation of treatment may be appropriate. Aggressive behavior or hostility should be monitored in patients beginning ADHD treatment. Methylphenidate may produce difficulties with visual accommodation and blurring of vision. Hematologic monitoring is advised during prolonged therapy. Growth should be monitored during treatment with stimulants, and patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.

The most common adverse reaction (>5%) reported in children and adolescents was abdominal pain upper. The most common adverse reactions (>10%) reported in adults were dry mouth, nausea, decreased appetite, headache, and insomnia.

Please see full U.S. Prescribing Information

© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2010. All rights reserved. Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy. This site is published by McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. which is solely responsible for its contents.

This information is intended for the use of our customers and healthcare professionals in the United States and Puerto Rico only. McNeil Pediatrics recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may be not be appropriate for use outside the United States and Puerto Rico.

CONCERTA® and OROS® are registered trademarks of ALZA Corporation © Ortho-McNeil-Janssen Pharmaceuticals, Inc. Titusville, NJ, USA. All rights reserved.

McNeil Pediatrics Logo



Last Modified Date: Jun 15 2010 at 16:01:18 EDT